Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Colorectal Cancer Treatments and Studies, and Gastric Cancer Management and Outcomes.
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold
Impact of<sup>68</sup>Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience
Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
The Role of<sup>68</sup>Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).
Deep learning detects virus presence in cancer histology
Abstract A042: A novel nonviral, nonintegrative DNA vector system for T-cell engineering
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific <i>In Silico</i> Models of Metastatic Colorectal Cancer
Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival
Morphological correlates of oxaliplatin induced peripheral neuropathy assessed by magnetic resonance neurography.
Abstract 3021: CCR5 inhibition: macrophage repolarization therapy for colorectal cancer
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
Bcl-xL is an oncogenic driver in colorectal cancer
Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.
Abstract A068: Determinants of efficacy in cancer immunovirotherapy
Abstract LB-287: Combining immunomics and genomics for immunotherapy of refractory and rare cancers
Abstract A110: Detailed resolution analysis reveals spatial heterogeneity of T cell distribution in the invasive margin of colorectal cancer liver metastases
Abstract B037: Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition